Get the Stockscreener App
1.395
1.06%
-0.015
NanoViricides Inc stock is traded at $1.395, with a volume of 121.72K.
It is down -1.06% in the last 24 hours and down -8.22% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.41
Open:
$1.4
24h Volume:
121.72K
Relative Volume:
0.79
Market Cap:
$24.59M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-1.9929
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
+1.09%
1M Performance:
-8.22%
6M Performance:
+3.33%
1Y Performance:
-22.50%
1-Day Range:
$1.37
$1.40
1-Week Range:
$1.34
$1.42
52-Week Range:
$0.94
$2.55
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.395 | 24.59M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan - Knoxville News Sentinel
NanoViricides' NV-387 Emerges as a Promising Broad-Spectrum Antiviral Against COVID-19 and Bird Flu - citybuzz -
Small cap wrap: Fineqia, NanoViricides, Standard Uranium... - Proactive Investors
NanoViricides touts antiviral NV-387 as tool against new COVID variant - Proactive financial news
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in AfricaPhase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu - The Columbus Dispatch
NanoViricides Advances Measles Drug Program as Global Outbreaks Rise - citybuzz -
NanoViricides Measles Drug Development Animal Study is Imminent - Akron Beacon Journal
Small cap wrap: NanoViricides, New Era Helium, Charbone Hydrogen, Voyageur Pharmaceuticals... - Proactive Investors
NanoViricides commissions animal study of broad-spectrum antiviral for measles - Proactive Investors
NanoViricides (NNVC) Advances Measles Drug Development | NNVC St - GuruFocus
Breakthrough Measles Drug Enters Critical Testing Phase as Global Cases Surge 10X - Stock Titan
Nanoviricides (NNVC) To Unveil 'Escape-Proof' Antiviral Platform At Major Biotech Convention - MENAFN.com
NanoViricides (NNVC) to Unveil 'Escape-Proof' Antiviral Platform at Major Biotech Convention - openPR.com
Gold Is Bullish, But Be Aware Of Deeper Intraday Pullback; Elliott Wave Intraday Analysis - The Globe and Mail
NanoViricides (NNVC) to Unveil ‘Escape-Proof’ Antiviral Platform at Major Biotech Convention - The Globe and Mail
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 - Lohud
NanoViricides to Showcase Breakthrough Antiviral Platform at BIO International Convention - citybuzz -
Hudbay Receives TSX Approval for Normal Course Issuer Bid - The Globe and Mail
NanoViricides to present at BIO International Convention 2025 in Boston - Proactive financial news
NanoViricides president backs FDA's targeted COVID booster policy shift - Proactive financial news
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan - ACCESS Newswire
Small cap wrap: NanoViricides, Trust Stamp, NextSource, StickIt... - Proactive financial news
NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox - Proactive Investors
NanoViricides: MPox ethics approval enables Phase 2 application - Proactive Investors
NanoViricides: Fiscal Q3 Earnings Snapshot - Huron Daily Tribune
Small cap wrap: atai, Black Swan Graphene, TNR Gold, NanoViricides... - Proactive financial news
NanoViricides progresses antiviral portfolio as measles and MPox threats rise - Proactive financial news
Measles Cases Are Increasing Globally; MPox Continues to Be a ThreatBroad-Spectrum Antiviral Drug Could Be the Solution - The Derrick
AMAT Likely to Beat Q2 Earnings Estimates: How to Play the Stock - The Globe and Mail
Small cap wrap: NanoViricides, Alvopetro, Polarean... - Proactive financial news
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC - Proactive financial news
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo - The Derrick
Renaissance Technologies LLC Buys 30,800 Shares of NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):